Economic Impact of Early Vs. Late Initiation of Atogepant for The Preventive Treatment of Migraine (P10-12.007)
Evaluate the economic impact of removing step edits prior to initiating atogepant for the preventive treatment of migraine, from a US payor perspective.
Authors
- Richard B. Lipton (ORCID: https://orcid.org/0000-0003-2652-2897)
- Brett Dabruzzo (ORCID: https://orcid.org/0009-0008-3048-2633)
- Rashmi B. Halker Singh (ORCID: https://orcid.org/0000-0002-4280-4440)
- Pranav Gandhi (ORCID: https://orcid.org/0009-0008-8317-7712)
- Jessica Ailani (ORCID: https://orcid.org/0000-0001-8106-4927)
- Amber Trujillo Lalla (ORCID: https://orcid.org/0000-0003-4267-1374)
- Karen Carr (ORCID: https://orcid.org/0000-0002-5870-1219)
Institutions
- Albert Einstein College of Medicine (US)
- WinnMed (US)
- MedStar Georgetown University Hospital (US)
- AbbVie (United States) (US)
- AbbVie (Japan)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208979
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00